CIPO Patents = 3 (Patent Applications = 8)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.1

ph-index = 10

Forward Citations = 520(Granted Patents)

Location History:

Monroe, CT (US) (1996 - 2005)
Oxford, CT (US) (2002 - 2005)
Oklahoma City, OK (US) (2010 - 2015)

Company Filing History:

11 out of 196

Alexion Pharmaceuticals, Inc.

patents

5 out of 197

Oklahoma Medical Research Foundation

Selexys Pharmaceuticals Corporation

where one patent can have more than one assignee

Years Active: 1996-2015

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9068001 - Anti-P-selectin antibodies (2015-06-30),

2. 8945565 - Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies (2015-02-03),

3. 7833530 - Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies (2010-11-16),

4. 6916654 - Universal donor cells (2005-07-12),

5. 6905657 - Methods and devices for storing and dispensing liquids (2005-06-14),

6. 6355245 - C5-specific antibodies for the treatment of inflammatory diseases (2002-03-12),

7. 6338820 - Apparatus for performing assays at reaction sites (2002-01-15),

8. 6100443 - Universal donor cells (2000-08-08),

9. 6074642 - Use of antibodies specific to human complement component C5 for the (2000-06-13),

10. 6040428 - Porcine E-selectin (2000-03-21),

11. 5891645 - Porcine E-selectin (1999-04-06),

12. 5871997 - Methods and compositions for protecting retroviral vector particles and (1999-02-16),

13. 5853722 - Use of C5-specific antibodies for reducing immune and hemostatic (1998-12-29),

14. 5847082 - Terminal complement inhibitor fusion proteins (1998-12-08),

15. 5705732 - Universal donor cells (1998-01-06),

Title: The Innovative Contributions of Scott A. Rollins in Antibody Development

Introduction: Scott A. Rollins, based in Monroe, Connecticut, is a distinguished inventor with an impressive portfolio of 18 patents to his name. His work in the realm of medical innovations, particularly in developing antibodies for therapeutic use, has positioned him as a notable figure in the biotechnology sector.

Latest Patents: Among his most recent inventions are anti-P-selectin antibodies, which specifically bind to P-selectin, inhibiting the binding of PSGL-1. These antibodies not only block this interaction but also induce the dissociation of preformed P-selectin/PSGL-1 complexes. His disclosures have uncovered a novel near N-terminal antibody binding domain (a conformational epitope) of P-selectin. This has led to the development of function-blocking antibodies, which can be chimeric, human, or humanized in nature. Rollins’ advancements in this area pave the way for targeted treatments for various inflammatory and thrombotic disorders. Importantly, screening methods for identifying such antibodies have also been disclosed in his patents.

Career Highlights: Throughout his professional journey, Scott has contributed significantly to the field of biomedical research, particularly during his tenure at renowned organizations such as Alexion Pharmaceuticals, Inc. and the Oklahoma Medical Research Foundation. His commitment to innovation in therapeutic antibody design underscores his substantial impact on medicine.

Collaborations: Scott's collaborations with esteemed colleagues like Stephen P. Squinto and Russell P. Rother have further enriched his research endeavors. These partnerships have enabled him to push the boundaries of scientific knowledge and create solutions that address critical medical needs.

Conclusion: Scott A. Rollins exemplifies the essence of innovation in biotechnology. His patents and collaborative work reflect a commitment to advancing therapeutic techniques that hold promise for treating complex health challenges. As research continues to evolve, Rollins' contributions will undoubtedly play a pivotal role in shaping future therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.